Testing effectiveness (Phase 2)Ended earlyNCT04434560What this trial is testingNeoadjuvant Immunotherapy in Brain MetastasesWho this might be right forBrain Metastases, Adult Sarah Sammons, MD 1
Testing effectiveness (Phase 2)Looking for participantsNCT06926790What this trial is testingNeoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)Who this might be right forLung Cancer - Non Small Cell The First Affiliated Hospital of Guangzhou Medical University 69
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07775040What this trial is testingSpatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II TrialWho this might be right forNon-Small Cell Lung Cancer Sichuan Cancer Hospital and Research Institute 43
Testing effectiveness (Phase 2)UnknownNCT04371796What this trial is testingSintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLCWho this might be right forLung DiseasesNeoplasmsRespiratory Tract Diseases+2 more Sichuan Cancer Hospital and Research Institute 20
Testing effectiveness (Phase 2)Active Not RecruitingNCT06268210What this trial is testingNeoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Yonsei University 160
Testing effectiveness (Phase 2)Study completedNCT03794544What this trial is testingNeoadjuvant Durvalumab Alone or in Combination With Novel Agents in Resectable Non-Small Cell Lung CancerWho this might be right forResectableEarly-stageNSCLC MedImmune LLC 84
Not applicableNot Yet RecruitingNCT07538193What this trial is testingIparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung CancerWho this might be right forCarcinoma, Non-Small-Cell Lung (NSCLC)Neoplasm StagingLymphatic Metastasis Tang-Du Hospital 28
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07241819What this trial is testingIvonescimab Monotherapy or in Combination With Chemotherapy as Neoadjuvant/Adjuvant Therapy for Resectable Non-small Cell Lung CancerWho this might be right forII-IIIB (T3N2) Resectable Non-small Cell Lung CancerPerioperative Peking University Cancer Hospital & Institute 66
Large-scale testing (Phase 3)Active Not RecruitingNCT04379635What this trial is testingComparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)Who this might be right forNon Small Cell Lung Cancer BeiGene 453
Testing effectiveness (Phase 2)Active Not RecruitingNCT05247684What this trial is testingAK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLCWho this might be right forResectable Non-small Cell Lung Cancer Akeso 90
Testing effectiveness (Phase 2)WithdrawnNCT04989283What this trial is testingTesting the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung CancerWho this might be right forLung Non-Small Cell CarcinomaStage IIB Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+1 more National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Active Not RecruitingNCT05633667What this trial is testingStudy of Novel Treatment Combinations in Patients With Lung CancerWho this might be right forLung CancerAdvanced or Metastatic Non-Small-Cell Lung CancerResectable Non-Small-Cell Lung Cancer Gilead Sciences 192
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07256509What this trial is testingSYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung CancerWho this might be right forNon-Small Cell Lung Cancer CSPC Megalith Biopharmaceutical Co.,Ltd. 120
Not applicableEnded earlyNCT02551211What this trial is testingAssociation Between Circulating Immune Cells and the Tumor Immune Contexture in Resectable Non-small Cell Lung CancerWho this might be right forResectable Non-small Lung Cancer University Hospital, Rouen 22
Testing effectiveness (Phase 2)Study completedNCT00198367What this trial is testingThree Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC)Who this might be right forNon-small Cell Lung Cancer Hospices Civils de Lyon 120
Testing effectiveness (Phase 2)Study completedNCT03217071What this trial is testingPembrolizumab With and Without Radiotherapy for Non-Small Cell Lung CancerWho this might be right forNon Small Cell Lung Cancer Sue Yom 12
Not applicableUnknownNCT06250829What this trial is testingModel to Predict pCR and IrAEs in Early Stage Non-small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Stage IB (Resectable)Non-small Cell Lung Cancer Stage II (Resectable)Non-small Cell Lung Cancer Stage ⅢA (Resectable) London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's 60
Testing effectiveness (Phase 2)Looking for participantsNCT04198766What this trial is testingStudy of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)Who this might be right forSolid TumorNon-Small Cell Lung CancerHead and Neck Cancer+5 more Inhibrx Biosciences, Inc 340
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07038460What this trial is testingPhase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLCWho this might be right forResectable Non-small Cell Lung Cancer Wen-zhao ZHONG 134
Post-approval studies (Phase 4)Looking for participantsNCT07279935What this trial is testingOsimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC.Who this might be right forNon-small Cell Lung Cancer AstraZeneca 100